title: Peri-stent contrast staining and very late stent thrombosis after sirolimus-eluting stent implantation: an observation from the RESTART (REgistry of Stent Thrombosis for review And Re-evaluaTion) angiographic substudy.
abstract: OBJECTIVE
  The aim of the study was to clarify the angiographic characteristics of stent thrombosis (ST) in relation to sirolimus-eluting stents (SES).
  
  
  RESULTS
  RESTART is a Japanese registry of SES-associated ST. As an angiographic substudy, coronary angiograms at baseline, at six to 12 months and at the time of ST were analysed. Angiograms of 313 patients (early ST [EST] 169 patients, late ST [LST] 59 patients, and very late ST [VLST] 85 patients) were investigated. Residual dissection post procedure was more frequently seen in the EST group. Stent fracture was more frequently seen in the VLST group than in the EST and LST groups (16.5%, 3.0%, and 3.4%, respectively; p<0.001). Peri-stent contrast staining (PSS), defined as contrast staining outside the stent contour extending to ≥20% of the stent diameter, was remarkably more prevalent in the VLST group than in the EST and LST groups (34.1%, 4.7%, and 6.8%, respectively; p<0.001).
  
  
  CONCLUSIONS
  Abnormal angiographic findings such as PSS and stent fracture were found significantly more frequently in lesions with VLST than in lesions with EST and LST.
authors: Division of Cardiology, Teikyo University Hospital, Tokyo, Japan.
authors: Ken
authors: K
authors: Kozuma
authors: Takeshi
authors: T
authors: Kimura
authors: Nobuaki
authors: N
authors: Suzuki
authors: Akiyoshi
authors: A
authors: Miyazawa
authors: Katsuhisa
authors: K
authors: Waseda
authors: Yasuhiro
authors: Y
authors: Honda
authors: Takeshi
authors: T
authors: Morimoto
authors: Tadanori
authors: T
authors: Aizawa
authors: Kazuaki
authors: K
authors: Mitsudo
authors: Shunichi
authors: S
authors: Miyazaki
authors: Tetsu
authors: T
authors: Yamaguchi
authors: Takaaki
authors: T
authors: Isshiki
mesh_terms: D054855:Drug-Eluting Stents; D005500:Follow-Up Studies; D006801:Humans; D012042:Registries; D020123:Sirolimus / Q000627:therapeutic use; D013194:Staining and Labeling; D015607:Stents; D013927:Thrombosis
chemical_list: D020123:Sirolimus